Jiaying Xin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiaying Xin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Bo Zhang
Social Service Department, Yunnan Institute for Drug Abuse, Kunming, China
1 shared publication - Cuixian Yang
Yunnan Provincial Hospital of Infectious Disease/Yunnan AIDS Care Center, Kunming, China
1 shared publication - Huiqin Li
Yunnan Infect Dis Hosp, Antiviral Clin Dept, Kunming, Yunnan, Peoples R China
1 shared publication - Huiqin Li
Antiviral Clinic Department, Yunnan Infectious Disease Hospital, Kunming, China
1 shared publication - Lizhu Hong
Science research and Education Department, Yunnan Institute for Drug Abuse, Kunming, China
1 shared publication - Ronghui Xie
Antiviral Clinic Department, Yunnan Infectious Disease Hospital, Kunming, China
1 shared publication
Latest Publications
- 30 August 2021
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 19 (4) , 368-376
Outcomes of Methadone Maintenance Therapy Combined with Rilpivirine/Efavirenz in Treatment-Naive HIV-Infected Patients
Background: Injecting drugs is associated with a high risk of HIV infection, alongside the risk of a drug overdose and mental health problems. Objective: To evaluate the effect of methadone maintenance treatment (MMT) combined with rilpivirine (RPV)-based regimens on drug use of HIV individuals. Methods: This study was a prospective, open-label, controlled, drug-drug interaction trial at a single center for 24 weeks. Participants on stable MMT were randomly divided into two groups administered RPV/TDF/3TC (RPV group) and EFV/TDF/3TC (EFV group), respectively. Adjustment doses of methadone were monitored for 12 weeks. HIV-1 RNA was used to evaluate the effects of antiretroviral therapy at week 24. Acute opioid withdrawal-, drug craving questionnaire- and MOSHIV scales were used to assess study outcomes. Results: 22 and 18 cases of HIV-infected drug users were recruited in the RPV and EFV groups, respectively. Thirty-one cases had completed monitoring and clinical evaluation at week 24. In the RPV and EFV groups, 32% and 56% of the participants had methadone dose adjustment, respectively, indicating a significantly lower rate in the RPV group. The rates of individuals with HIV RNA levels from 50-500 copies/ml were 94% (RPV group) and 90% (EFV group). The drug craving questionnaire scale scores decreased in both groups. After one week of treatments, acute opioid withdrawal scale scores increased in both groups, with no significant difference between them. Conclusion: Concomitant administration of RPV does not significantly affect methadone and could decrease withdrawal symptoms. An RPV-based regimen may be used as first-line treatment in IDUs with HIV infection.
- 30 August 2021
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 19 (4) , 368-376
Outcomes of Methadone Maintenance Therapy Combined with Rilpivirine/Efavirenz in Treatment-Naive HIV-Infected Patients
Background: Injecting drugs is associated with a high risk of HIV infection, alongside the risk of a drug overdose and mental health problems. Objective: To evaluate the effect of methadone maintenance treatment (MMT) combined with rilpivirine (RPV)-based regimens on drug use of HIV individuals. Methods: This study was a prospective, open-label, controlled, drug-drug interaction trial at a single center for 24 weeks. Participants on stable MMT were randomly divided into two groups administered RPV/TDF/3TC (RPV group) and EFV/TDF/3TC (EFV group), respectively. Adjustment doses of methadone were monitored for 12 weeks. HIV-1 RNA was used to evaluate the effects of antiretroviral therapy at week 24. Acute opioid withdrawal-, drug craving questionnaire- and MOSHIV scales were used to assess study outcomes. Results: 22 and 18 cases of HIV-infected drug users were recruited in the RPV and EFV groups, respectively. Thirty-one cases had completed monitoring and clinical evaluation at week 24. In the RPV and EFV groups, 32% and 56% of the participants had methadone dose adjustment, respectively, indicating a significantly lower rate in the RPV group. The rates of individuals with HIV RNA levels from 50-500 copies/ml were 94% (RPV group) and 90% (EFV group). The drug craving questionnaire scale scores decreased in both groups. After one week of treatments, acute opioid withdrawal scale scores increased in both groups, with no significant difference between them. Conclusion: Concomitant administration of RPV does not significantly affect methadone and could decrease withdrawal symptoms. An RPV-based regimen may be used as first-line treatment in IDUs with HIV infection.